Ultrasound-enhanced ocular delivery of dexamethasone sodium phosphate: an in vivo study

• Published in: Journal of therapeutic ultrasound Vol. 2; no. 1; p. 6
• Main Authors: Nabili, Marjan, Shenoy, Aditi, Chawla, Shawn, Mahesh, Sankaranarayana, Liu, Ji, Geist, Craig, Zderic, Vesna
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 31.03.2014; BioMed Central
• Subjects: Care and treatment; Drug delivery systems; Drugs; Eye diseases; Health aspects; Physiological aspects; Steroids; Vehicles; Sonophoresis; Therapeutic ultrasound; Cornea; Drug delivery; Dexamethasone sodium phosphate; Ocular diseases
• ISSN: 2050-5736; 2050-5736
• DOI: 10.1186/2050-5736-2-6

The eye's unique anatomy and its physiological and anatomical barriers can limit effective drug delivery into the eye. An in vivo study was designed to determine the effectiveness and safety of ultrasound application in enhancing drug delivery in a rabbit model. Permeability of a steroid ophthalmic drug, dexamethasone sodium phosphate, was investigated in ultrasound- and sham-treated cases. For this study, an eye cup filled with dexamethasone sodium phosphate was placed on the cornea. Ultrasound was applied at intensity of 0.8 W/cm(2) and frequency of 400 or 600 kHz for 5 min. The drug concentration in aqueous humor samples, collected 90 min after the treatment, was determined using chromatography methods. Light microscopy observations were done to determine the structural changes in the cornea as a result of ultrasound application. An increase in drug concentration in aqueous humor samples of 2.8 times (p < 0.05) with ultrasound application at 400 kHz and 2.4 times (p < 0.01) with ultrasound application at 600 kHz was observed as compared to sham-treated samples. Histological analysis showed that the structural changes in the corneas exposed to ultrasound predominantly consisted of minor epithelial disorganization. Ultrasound application enhanced the delivery of an anti-inflammatory ocular drug, dexamethasone sodium phosphate, through the cornea in vivo. Ultrasound-enhanced ocular drug delivery appears to be a promising area of research with a potential future application in a clinical setting.